<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27982270</article-id><article-id pub-id-type="pmc">5137390</article-id><article-id pub-id-type="doi">10.5935/abc.20160166</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group><subject>Heart Failure</subject></subj-group></subj-group></article-categories><title-group><article-title>Elevated Heart Rate is Associated with Cardiac Denervation in
Patients with Heart Failure: A 123-Iodine-MIBG Myocardial Scintigraphy
Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Villacorta</surname><given-names>Aline Sterque</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Villacorta</surname><given-names>Humberto</given-names><suffix>Junior</suffix></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>de Souza</surname><given-names>Jenne Serr&#x000e3;o</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Teixeira</surname><given-names>Jos&#x000e9; Ant&#x000f4;nio Caldas</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Muradas</surname><given-names>Maria Clara S. S. S.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Alves</surname><given-names>Christiane Rodrigues</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Precht</surname><given-names>Bernardo Campan&#x000e1;rio</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Porto</surname><given-names>Pilar</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Ubaldo</surname><given-names>Let&#x000ed;cia</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Mesquita</surname><given-names>Cl&#x000e1;udio Tinoco</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>da N&#x000f3;brega</surname><given-names>Ant&#x000f4;nio Cl&#x000e1;udio Lucas</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><aff id="aff1">Universidade Federal Fluminense, Niter&#x000f3;i, RJ - Brazil</aff></contrib-group><author-notes><corresp id="c1"><bold>Mailing Address: Humberto Villacorta</bold>, Hospital
Universit&#x000e1;rio Ant&#x000f4;nio Pedro. Cardiology Division. Rua
Marqu&#x000ea;s do Paran&#x000e1; 303, Postal Code 24033-900, Niter&#x000f3;i, RJ -
Brazil. E-mail: <email>huvillacorta@globo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>11</month><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>11</month><year>2016</year></pub-date><volume>107</volume><issue>5</issue><fpage>455</fpage><lpage>459</lpage><history><date date-type="received"><day>28</day><month>4</month><year>2016</year></date><date date-type="rev-recd"><day>14</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2016</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>In the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine
Trial (SHIFT), heart rate (HR) reduction with ivabradine was associated with
improved survival and reduced hospitalizations in patients with heart
failure (HF). The mechanisms by which elevated HR increases mortality are
not fully understood.</p></sec><sec><title>Objective</title><p>To assess the relationship of baseline HR with clinical, neurohormonal and
cardiac sympathetic activity in patients with chronic HF and elevated
HR.</p></sec><sec><title>Method</title><p>Patients with chronic HF who were in sinus rhythm and had resting HR&#x0003e;70
bpm despite optimal medical treatment were included in a randomized,
double-blind study comparing ivabradine versus pyridostigmine. This report
refers to the baseline data of 16 initial patients. Baseline HR (before
randomization to one of the drugs) was assessed, and patients were
classified into two groups, with HR below or above mean values. Cardiac
sympathetic activity was assessed by 123-iodine-metaiodobenzylguanidine
myocardial scintigraphy.</p></sec><sec><title>Results</title><p>Mean HR was 83.5&#x000b1;11.5 bpm (range 72 to 104), and seven (43.7%)
patients had HR above the mean. These patients had lower 6-min walk distance
(292.3&#x000b1;93 vs 465.2&#x000b1;97.1 m, p=0.0029), higher values of
N-Terminal-proBNP (median 708.4 vs 76.1, p=0.035) and lower late
heart/mediastinum rate, indicating cardiac denervation (1.48&#x000b1;0.12 vs
1.74&#x000b1;0.09, p&#x0003c;0.001).</p></sec><sec><title>Conclusion</title><p>Elevated resting HR in patients with HF under optimal medical treatment was
associated with cardiac denervation, worse functional capacity, and
neurohormonal activation.</p></sec></abstract><kwd-group><kwd>Heart Rate</kwd><kwd>Denervation</kwd><kwd>Heart Failure</kwd><kwd>Myocardium / radionuclide imaging</kwd><kwd>Sympathetic Nervous System</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The treatment of heart failure (HF) has improved substantially with the introduction
of angiotensin-converting enzyme inhibitors, mineralocorticoid receptor antagonists
and beta blockers.<sup><xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref></sup> Among many effects related to betablockers, the
reduction in heart rate (HR) has been recognized for a long time. Many patients with
HF are under beta blockers, and some of them remain with HR above 70 bpm despite
maximum doses of these medications. Since resting HR in HF is related to increased
cardiovascular risk,<sup><xref rid="r4" ref-type="bibr">4</xref></sup> it is
clinically relevant to search for alternatives to reduce HR.</p><p>In the Systolic Heart Failure Treatment With the <italic>I</italic>f Inhibitor
Ivabradine Trial (SHIFT),<sup><xref rid="r4" ref-type="bibr">4</xref></sup>
Ivabradine was compared with placebo in patients with HF and HR above 70 bpm,
despite optimal medical treatment. Ivabradine use was associated with improved
outcomes, defined as cardiovascular death or hospital admission for HF. The SHIFT
Trial confirmed the important role of HR in the pathophysiology of HF.</p><p>Increased myocardial sympathetic activity is a prominent feature of HF and is
associated with progressive myocardial remodeling, decline in left ventricular
function, and worsening symptoms<sup><xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref></sup>. Increased neuronal release of
norepinephrine (NE) is usually accompanied by decreased neuronal NE reuptake due to
post-transcriptional downregulation of the cardiac NE transporter.<sup><xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref></sup>
</p><p>The decrease in the NE reuptake mechanism has been successfully assessed by
radionuclide imaging with the iodine-123-labeled NE analog metaiodobenzylguanidine
(123-I-MIBG). The NE transporter mediates uptake of 123-I-MIBG into myocardial
sympathetic nerve endings, and because the compound is not metabolized, the amount
of 123-I-MIBG retention over several hours after administration is a reflection of
neuronal integrity.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> Reduced
myocardial 123-I-MIBG uptake has been demonstrated to be an independent predictor of
adverse long-term outcome, and improvement in 123-I-MIBG uptake is observed in
response to effective HF therapy.<sup><xref rid="r10" ref-type="bibr">10</xref>-<xref rid="r12" ref-type="bibr">12</xref></sup>
</p><p>Cardiac sympathetic activity is strongly related to HR. Since the mechanisms by which
elevated HR increases mortality are not fully understood, we sought to assess the
relationship of baseline resting HR with clinical, neuro-hormonal and cardiac
sympathetic activity in patients with chronic HF and elevated HR, despite optimal
medical treatment.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>This report is part of a larger study, a randomized clinical trial comparing
ivabradine with pyridostigmine. It refers to baseline data (before randomization
to one of the drugs) of the 16 initial patients included in the trial. Inclusion
criteria were the presence of overt HF, sinus rhythm, ejection fraction &#x0003c;50%
as assessed by echocardiography (Sympson method), and resting HR over 70 bpm
despite optimal medical treatment, including maximum tolerated doses of
betablockers. Exclusion criteria were patients with pacemakers, serum creatinine
&#x0003e;3 mg/dL, acute myocarditis, active myocardial ischemia, asthma, glaucoma,
urinary obstruction, thyroid dysfunction, and patients expected to be submitted
to myocardial revascularization or device implantation in the next 6 months.
Resting HR was assessed at bedside, after at least 5-min rest, on two
consecutive visits before randomization. The Ethics Committee of our hospital
approved the study protocol.</p><p>Patients were classified according to baseline HR into two groups: a) group 1,
patients with HR below or equal to mean HR in the entire population; and b)
group 2, patients with the highest HR, above mean HR. Demographic, clinical,
laboratorial, and image data were compared between groups. Drug prescription did
not change over the last 3 months. Eligible patients who agreed to participate
in the study signed a consent form after receiving verbal and written
information about the study.</p></sec><sec><title>Myocardial scintigraphy, biomarkers, and functional capacity
assessment</title><p>Cardiac sympathetic activity was assessed via 123-I-MIBG myocardial scintigraphy.
Early and late myocardial anterior planar images were respectively acquired 30
min and 4 h after the radiotracer infusion. Derived from the scintigraphic
planar images, semi-quantitative myocardial 123-I-MIBG uptake and washout
reflected functional/structural cardiac innervation and sympathetic tone,
respectively. The heart/mediastinum ratio (H/M) was determined from the
counts/pixel in a visually drawn heart region of interest divided by the
counts/pixel in a 7x7 pixel mediastinum region of interest in the mid-line upper
chest positioned to reflect the location with lowest activity (i.e., nonspecific
background).</p><p>Neuro-hormonal activation was assessed by the measurement of N-terminal
pro-B-Type natriuretic peptide (NT-proBNP) (Roche Diagnostics, Inc.,
Indianapolis, Indiana) in blood samples. Functional capacity was assessed by
6-min walk test.</p></sec><sec><title>Cardiopulmonary exercise testing</title><p>The MedGraphics (MGC) VO2000 metabolic analyzer was used (Imbrasport, Porto
Alegre, Rio Grande do Sul State, Brazil) together with the Ergo PC Elite 13
system and Centurion 300 treadmill (MicroMed, Bras&#x000ed;lia, DF, Brazil). The
gas analyzer was calibrated before each test by the Autocal system in a
ventilated setting, and biological calibration was performed monthly.
Maintenance of the equipment was carried out by the equipment representative
every three months (CAEL, Rio de Janeiro, RJ, Brazil).</p><p>The cardiopulmonary exercise test (CPET) consisted of recording of baseline
parameters in the first two minutes, a one-minute warm-up at 1 km/h, followed by
the ramp protocol. Data analysis was performed by the ErgoPCElite program for
Windows 13W (MicroMed, Bras&#x000ed;lia, Brazil).</p><p>At each minute, hemodynamic and electrocardiographic variables were measured, as
well as the stress perception using the Borg scale from 0 to 10. The recovery
phase took place with the patient seated. The analysis was conducted by two
judges, who evaluated the following criteria: VE/VCO<sub>2</sub> slope, presence
of periodic ventilation and establishment of the ventilatory threshold I, from
then on called the anaerobic threshold (AT). For the AT, the equivalent
ventilatory curves were considered for VO<sub>2</sub> and VCO<sub>2</sub>, in
addition to the exhaled VO<sub>2</sub> and VCO<sub>2</sub> fraction curves. The
peak VO<sub>2</sub> was defined as the highest value obtained up to the final
thirty seconds, or during the ten seconds of the immediate recovery phase.</p></sec><sec><title>Total body water assessment</title><p>Bioelectrical impedance vector analysis (BIVA) was used to assess total body
water. This method utilizes the EFG Renal software (Akern, Pontassieve,
Florence, Italy) for estimating the parameters of resistance, reactance, and
phase angle. Then, the hydration index (HI) was calculated to estimate total
body water. Normal HI range is 72.7% to 74.3%; values above this range indicate
congestion and values below this cutoff indicate dehydration.</p></sec><sec><title>Statistical analysis</title><p>Data are presented as mean &#x000b1; SD, except for NT-proBNP, expressed as median
and interquartile ranges. Categorical variables were analyzed by the chi-square
test. A two-tailed unpaired Student's t-test was performed to identify
significant between-group differences in normally distributed variables.
Mann-Whitney test was used for non-normal data. Statistical significance was
accepted at the 0.05 level. The statistical analyses were performed using
MedCalc <sup>&#x000ae;</sup> software (version 14.12.0, Ostend, Belgium).</p></sec></sec><sec sec-type="results"><title>Results</title><p>The medications for HF used by the study patients are shown in <xref ref-type="table" rid="t1">Table 1</xref>. Mean baseline HR was 83&#x000b1;11.5 bpm. Seven (43.7%)
patients were in the group with the highest HR (HR above 83 bpm). As shown in <xref ref-type="table" rid="t2">Table 2</xref>, patients with the highest HR were more
likely to be in III/IV New York Heart Association (NYHA) functional class, and had
significantly worse functional capacity as assessed by 6-min walk test. There was no
difference in systemic congestion between groups as assessed by either limb edema or
BIVA. Patients with the highest HR also had higher values of NT-proBNP and lower
late (H/M) rate (<xref ref-type="fig" rid="f1">Figure 1</xref>), indicating cardiac
denervation. No difference between groups was observed regarding early H/M rate or
washout rate.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Medications for heart failure used by the study population</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Medications for heart failure</th><th align="center" rowspan="1" colspan="1">Results <break/>n=16</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Carvedilol</td><td align="center" rowspan="1" colspan="1">16 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose (mg/day)</td><td align="center" rowspan="1" colspan="1">47.4&#x000b1;7.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Enalapril</td><td align="center" rowspan="1" colspan="1">8 (50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose (mg/day)</td><td align="center" rowspan="1" colspan="1">34.4&#x000b1;11.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Captopril</td><td align="center" rowspan="1" colspan="1">2 (12.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose (mg/day)</td><td align="center" rowspan="1" colspan="1">150&#x000b1;0</td></tr><tr><td align="left" rowspan="1" colspan="1">Losartan</td><td align="center" rowspan="1" colspan="1">6 (37.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose (mg/day)</td><td align="center" rowspan="1" colspan="1">100&#x000b1;0</td></tr><tr><td align="left" rowspan="1" colspan="1">Spironolactone</td><td align="center" rowspan="1" colspan="1">15 (93.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose (mg/day)</td><td align="center" rowspan="1" colspan="1">25&#x000b1;0</td></tr><tr><td align="left" rowspan="1" colspan="1">Furosemide</td><td align="center" rowspan="1" colspan="1">13 (81.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose (mg/day)</td><td align="center" rowspan="1" colspan="1">53.3&#x000b1;24.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Isosorbide dinitrate and hydralazine</td><td align="center" rowspan="1" colspan="1">8 (50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose of hydralazine (mg/day)</td><td align="center" rowspan="1" colspan="1">157&#x000b1;85.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose of isosorbide (mg/day)</td><td align="center" rowspan="1" colspan="1">32.6&#x000b1;6.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Digoxin</td><td align="center" rowspan="1" colspan="1">5 (31.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose (mg/day)</td><td align="center" rowspan="1" colspan="1">0.18&#x000b1;0.08</td></tr></tbody></table></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Demographic, clinical, and laboratorial characteristics of heart failure
patients separated into two groups according to heart rate values below or
above the mean (83 bpm)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">HR&#x02264;83 bpm <break/>n=9</th><th align="center" rowspan="1" colspan="1">HR&#x0003e;83 bpm <break/>n=7</th><th align="center" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">50.1&#x000b1;13.6</td><td align="center" rowspan="1" colspan="1">52.4&#x000b1;12.5</td><td align="center" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Male gender</td><td align="center" rowspan="1" colspan="1">4 (44.4%)</td><td align="center" rowspan="1" colspan="1">5 (71.4%)</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">III/IV NYHA functional class</td><td align="center" rowspan="1" colspan="1">1 (11.1%)</td><td align="center" rowspan="1" colspan="1">4 (44.4%)</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Limb edema</td><td align="center" rowspan="1" colspan="1">3 (33.3%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic cardiomyopathy</td><td align="center" rowspan="1" colspan="1">2 (22.2%)</td><td align="center" rowspan="1" colspan="1">1 (14.3%)</td><td align="center" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Left bundle branch block</td><td align="center" rowspan="1" colspan="1">5 (55.6%)</td><td align="center" rowspan="1" colspan="1">2 (28.6%)</td><td align="center" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Minnesota Questionnaire</td><td align="center" rowspan="1" colspan="1">36.7&#x000b1;18.2</td><td align="center" rowspan="1" colspan="1">29.7&#x000b1;7.2</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">1.06&#x000b1;0.26</td><td align="center" rowspan="1" colspan="1">0.97&#x000b1;0.29</td><td align="center" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">6-minute walk distance (m)</td><td align="center" rowspan="1" colspan="1">465.2&#x000b1;97.1</td><td align="center" rowspan="1" colspan="1">292.3&#x000b1;93</td><td align="center" rowspan="1" colspan="1">0.0029</td></tr><tr><td align="left" rowspan="1" colspan="1">VO<sub>2</sub> (mL/min)</td><td align="center" rowspan="1" colspan="1">17.23&#x000b1;3.62</td><td align="center" rowspan="1" colspan="1">14.5&#x000b1;5.19</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">LV ejection fraction (%)</td><td align="center" rowspan="1" colspan="1">35.4&#x000b1;15.6</td><td align="center" rowspan="1" colspan="1">40.5&#x000b1;18.8</td><td align="center" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydration index (BIVA)</td><td align="center" rowspan="1" colspan="1">75.8&#x000b1;3.75</td><td align="center" rowspan="1" colspan="1">73.6&#x000b1;0.05</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">NT-proBNP (pg/mL)</td><td align="center" rowspan="1" colspan="1">378 (140 - 745)</td><td align="center" rowspan="1" colspan="1">800 (589 - 990)</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Early H/M rate</td><td align="center" rowspan="1" colspan="1">1.76&#x000b1;0.15</td><td align="center" rowspan="1" colspan="1">1.69&#x000b1;0.13</td><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Late H/M rate</td><td align="center" rowspan="1" colspan="1">1.74&#x000b1;0.09</td><td align="center" rowspan="1" colspan="1">1.48&#x000b1;0.12</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Washout rate (%)</td><td align="center" rowspan="1" colspan="1">37.4&#x000b1;9</td><td align="center" rowspan="1" colspan="1">34.3&#x000b1;5</td><td align="center" rowspan="1" colspan="1">0.42</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>BIVA: bioelectrical impedance vector analysis; LV: left ventricle;
NT-proBNP: N-terminal pro-B type natriuretic peptide; NYHA: New York
Heart Association; H/M: heart/ mediastinum; VO<sub>2</sub>: peak oxygen
consumption.</p></fn></table-wrap-foot></table-wrap><p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Late heart/mediastinum (H/M) ratio in patients with chronic heart failure
according to heart rate (HR) values below or above the population
mean</p></caption><graphic xlink:href="abc-107-05-0455-gf01"/></fig>
</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The main finding of our study was that in patients with chronic HF under optimal
medical treatment, elevated HR correlated with neurohormonal activation and cardiac
denervation. Cardiac sympathetic abnormalities have been shown to predict outcomes
in HF. In the ADMIRE-HF (Adre View Myocardial Imaging for Risk Evaluation in Heart
Failure) Study, 961 subjects with NYHA functional class II/III HF and left
ventricular ejection fraction &#x02264;35% were included and followed up for up to 2
years.<sup><xref rid="r13" ref-type="bibr">13</xref></sup> Event rates were
higher for patients with late H/M ratio &#x02264;1.60 as compared with patients above
this cutoff (35% vs 15%, p&#x0003c;0.001). Of note, H/M ratio predicted events due to HF
progression and arrhythmic events as well. It is important to mention that in the
present study, patients with the highest HR had H/M ratio of 1.48, which is within
the range shown to predict events in the ADMIRE-HF Study.</p><p>Regional cardiac denervation as assessed by positron emission tomography (PET) has
also been associated with sudden cardiac arrest. In the PAREPET (Prediction of
Arrhythmic Events with Positron Emission Tomography) study, patients in the highest
tertile had the highest rates of sudden cardiac arrest.<sup><xref rid="r14" ref-type="bibr">14</xref></sup> Thus, either regional or global cardiac
denervation indicates an adverse prognosis in patients with HF.<sup><xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref></sup>
</p><p>In the present study, patients with the highest HR were also the sickest patients as
assessed by NYHA functional class, 6-min walk test, and NT-proBNP levels. Of note,
such alterations could not be explained by a congestive state. Our study does not
permit any speculation regarding a cause-effect relationship between elevated HR and
heart denervation. HR could be just a marker of these abnormalities. However, the
hypothesis that HR itself is the cause of denervation and high natriuretic peptide
levels is supported by the findings of the SHIFT study, in which the reduction of HR
with ivabradine, a drug with no neurohormonal activity, led to improvement of
outcomes.<sup><xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r15" ref-type="bibr">15</xref></sup> Besides, the use of ivabradine has been shown to
reduce the levels of natriuretic peptides and improve functional capacity.<sup><xref rid="r16" ref-type="bibr">16</xref></sup> This hypothesis however needs to
be confirmed in further studies.</p><p>We found that a simple bedside tool was related to reduced late H/M ratio, reflecting
a denervated myocardium. Thus, elevated HR could serve as a screening tool to a more
comprehensive evaluation that would include tests such as 123-I-MIBG myocardial
scintigraphy in patients with HF. Additionally, HR is a target for treatment in
chronic HF and any drug that reduces HR may have a favorable impact on outcomes. A
limitation to the present study refers to the small number of patients and the
cross-sectional design of the study.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In summary, we found that in patients with chronic HF and systolic dysfunction,
elevated resting HR despite optimal medical treatment was associated with cardiac
denervation as assessed by 123-I-MIBG myocardial scintigraphy and neurohormonal
activation. These alterations may explain, at least in part, the worse outcomes
observed in such patients.</p></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Conception and design of the research: Villacorta AS, Villacorta Junior H,
N&#x000f3;brega ACL; Acquisition of data: Villacorta AS, Souza JS, Teixeira JAC,
Muradas MCSSS, Alves CR, Precht BC, Porto P, Ubaldo L, Mesquita CT; Analysis and
interpretation of the data: Villacorta AS, Villacorta Junior H, Mesquita CT,
N&#x000f3;brega ACL; Statistical analysis: Villacorta Junior H, N&#x000f3;brega
ACL; Obtaining financing: Villacorta AS, Villacorta Junior H, Mesquita CT,
N&#x000f3;brega ACL; Writing of the manuscript: Villacorta AS, Villacorta Junior
H; Critical revision of the manuscript for intellectual content: Villacorta AS,
Villacorta Junior H, Souza JS, Teixeira JAC, Muradas MCSSS, Alves CR, Precht BC,
Porto P, Ubaldo L, Mesquita CT, N&#x000f3;brega ACL.</p></fn><fn fn-type="COI-statement"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="supported-by"><p><bold>Sources of Funding</bold></p><p>This study was funded by FAPERJ.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This article is part of the thesis of Doctoral submitted by Aline Sterque
Villacorta, from Universidade Federal Fluminense.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was funded by Foundation for Research Support of the State of Rio de
Janeiro (Funda&#x000e7;&#x000e3;o Carlos Chagas Filho de Amparo &#x000e0; Pesquisa do
Estado do Rio de Janeiro - FAPERJ).</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The SOLVD investigators</collab></person-group><article-title>Effect of enalapril on survival in patients with reduced left
ventricular ejection fraction and congestive heart failure</article-title><source>N Engl J Med</source><year>1991</year><volume>325</volume><issue>5</issue><fpage>294</fpage><lpage>302</lpage></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>M</given-names></name><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Cohn</surname><given-names>JN</given-names></name><name><surname>Colucci</surname><given-names>WS</given-names></name><name><surname>Fowler</surname><given-names>MB</given-names></name><name><surname>Gilbert</surname><given-names>EM</given-names></name><etal/></person-group><article-title>The effect of carvedilol on morbidity and mortality in patients
with chronic heart failure. U.S. Carvedilol Heart Failure Study
Group</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><issue>21</issue><fpage>1349</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">8614419</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Remme</surname><given-names>J</given-names></name><name><surname>Cody</surname><given-names>R</given-names></name><name><surname>Castaigne</surname><given-names>A</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><etal/></person-group><article-title>The effect of spironolactone in morbidity and mortality in
patients with severe heart failure. Randomized Aldactone Evaluation Study
Investigators</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><issue>10</issue><fpage>709</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">10471456</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swedberg</surname><given-names>K</given-names></name><name><surname>Komajda</surname><given-names>M</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><name><surname>Borer</surname><given-names>JS</given-names></name><name><surname>Ford</surname><given-names>Y</given-names></name><name><surname>Dubost-Brama</surname><given-names>A</given-names></name><etal/></person-group><article-title>Ivabradine and outcomes in chronic heart failure (SHIFT): a
randomized placebo-controlled study</article-title><source>Lancet</source><comment>nullErratum in Lancet. 2010;376(9757):1988.</comment><year>2010</year><volume>376</volume><issue>9744</issue><fpage>875</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">20801500</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn</surname><given-names>JN</given-names></name><name><surname>Levine</surname><given-names>TB</given-names></name><name><surname>Olivari</surname><given-names>MT</given-names></name><name><surname>Garberg</surname><given-names>V</given-names></name><name><surname>Lura</surname><given-names>D</given-names></name><name><surname>Francis</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Plasma norepinephrine as a guide to prognosis in patients with
chronic congestive heart failure</article-title><source>N Engl J Med</source><year>1984</year><volume>311</volume><issue>13</issue><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">6382011</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leimbach</surname><given-names>WN</given-names><suffix>Jr</suffix></name><name><surname>Wallin</surname><given-names>BG</given-names></name><name><surname>Victor</surname><given-names>RG</given-names></name><name><surname>Aylward</surname><given-names>PE</given-names></name><name><surname>Sundlof</surname><given-names>G</given-names></name><name><surname>Mark</surname><given-names>AL</given-names></name></person-group><article-title>Direct evidence from intraneural recordings for increased central
sympathetic outflow in patients with heart failure</article-title><source>Circulation</source><year>1986</year><volume>73</volume><issue>5</issue><fpage>913</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">3698236</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ungerer</surname><given-names>M</given-names></name><name><surname>Hartmann</surname><given-names>F</given-names></name><name><surname>Karoglan</surname><given-names>M</given-names></name><name><surname>Chlistalla</surname><given-names>A</given-names></name><name><surname>Ziegler</surname><given-names>S</given-names></name><name><surname>Richardt</surname><given-names>G</given-names></name><etal/></person-group><article-title>Regional in vivo and in vitro characterization of autonomic
innervation in cardiomyopathic human heart</article-title><source>Circulation</source><year>1998</year><volume>97</volume><issue>2</issue><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">9445170</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backs</surname><given-names>J</given-names></name><name><surname>Haunstetter</surname><given-names>A</given-names></name><name><surname>Gerber</surname><given-names>SH</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Borst</surname><given-names>MM</given-names></name><name><surname>Strasser</surname><given-names>RH</given-names></name><etal/></person-group><article-title>The neuronal norepinephrine transporter in experimental heart
failure: evidence for a post-transcriptional downregulation</article-title><source>J Mol Cell Cardiol</source><year>2001</year><volume>33</volume><issue>3</issue><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">11181015</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisson</surname><given-names>JC</given-names></name><name><surname>Wieland</surname><given-names>DM</given-names></name></person-group><article-title>Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical
studies</article-title><source>Am J Physiol Imaging</source><year>1986</year><volume>1</volume><issue>2</issue><fpage>96</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">3330445</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>T</given-names></name><name><surname>Nakata</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>A</given-names></name><name><surname>Yuda</surname><given-names>S</given-names></name><name><surname>Tsuchihashi</surname><given-names>K</given-names></name><name><surname>Travin</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Assessment of underlying etiology and cardiac sympathetic
innervation to identify patients at high risk of cardiac
death</article-title><source>J Nucl Med</source><year>2001</year><volume>42</volume><issue>12</issue><fpage>1757</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">11752070</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasama</surname><given-names>S</given-names></name><name><surname>Toyama</surname><given-names>T</given-names></name><name><surname>Kumakura</surname><given-names>H</given-names></name><name><surname>Takayama</surname><given-names>Y</given-names></name><name><surname>Ichikawa</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Spironolactone improves cardiac sympathetic nerve activity and
symptoms in patients with congestive heart failure</article-title><source>J Nucl Med</source><year>2002</year><volume>43</volume><issue>10</issue><fpage>1279</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">12368364</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>D</given-names></name><name><surname>Belin</surname><given-names>A</given-names></name><name><surname>Amar</surname><given-names>MH</given-names></name><name><surname>Dorlas</surname><given-names>Y</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Grollier</surname><given-names>G</given-names></name><etal/></person-group><article-title>Improvement of cardiac neuronal function after carvedilol
treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic
study</article-title><source>J Nucl Med</source><year>2000</year><volume>41</volume><issue>5</issue><fpage>845</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">10809201</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>AF</given-names></name><name><surname>Senior</surname><given-names>R</given-names></name><name><surname>Cerqueira</surname><given-names>MD</given-names></name><name><surname>Wong</surname><given-names>ND</given-names></name><name><surname>Thomas</surname><given-names>GS</given-names></name><name><surname>Lopez</surname><given-names>VA</given-names></name><etal/><collab>ADMIRE-HF Investigators</collab></person-group><article-title>Myocardial iodine-123 meta-iodobenzylguanidine imaging and
cardiac events in heart failure: results of the prospective ADMIRE-HF (Adre
View Myocardial Imaging for risk evaluation in heart failure)
study</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><issue>20</issue><fpage>2212</fpage><lpage>2221</lpage><pub-id pub-id-type="pmid">20188504</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallavollita</surname><given-names>JA</given-names></name><name><surname>Heavey</surname><given-names>BM</given-names></name><name><surname>Luisi</surname><given-names>AJ</given-names><suffix>Jr</suffix></name><name><surname>Michalek</surname><given-names>SM</given-names></name><name><surname>Baldwa</surname><given-names>S</given-names></name><name><surname>Mashtare</surname><given-names>TL</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Regional myocardial sympathetic denervation predicts the risk of
sudden cardiac arrest in ischemic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><issue>2</issue><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">24076296</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><name><surname>Swedberg</surname><given-names>K</given-names></name><name><surname>Komajda</surname><given-names>M</given-names></name><name><surname>Borer</surname><given-names>JS</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name><name><surname>Dubost-Brama</surname><given-names>A</given-names></name><collab>SHIFT Investigators</collab><etal/></person-group><article-title>Heart rate as a risk factor in Chronic Heart Failure (SHIFT): the
association between heart rate and outcomes in a randomized
placebo-controlled trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9744</issue><fpage>886</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">20801495</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarullo</surname><given-names>MF</given-names></name><name><surname>Fazio</surname><given-names>G</given-names></name><name><surname>Puccio</surname><given-names>D</given-names></name><name><surname>Fasullo</surname><given-names>S</given-names></name><name><surname>Paterna</surname><given-names>S</given-names></name><name><surname>Novo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of "off-label" use of ivabradine on exercise capacity, gas
exchange, functional class, quality of life, and neurohormonal modulation in
patients with ischemic chronic heart failure</article-title><source>J Cardiovasc Pharmacol Ther</source><year>2010</year><volume>15</volume><issue>4</issue><fpage>349</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">20940450</pub-id></element-citation></ref></ref-list></back></article>